CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 9 enrolled
Drug / intervention
MSC Secretome Eye Dropsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05204329
NCT05204329Early Ph 1Completed
CompareCT.gov

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

University of Illinois at Chicago·interventional·Posted Jan 24, 2022·Updated Jan 29, 2026

In Brief

A Early Phase 1 clinical trial evaluating MSC Secretome Eye Drops for Mesenchymal Stromal Cells and 3 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesenchymal Stromal Cells, Cornea, Corneal Defect, Corneal Epithelium Defect
CountriesUnited States
CollaboratorsNational Eye Institute (NEI), National Institutes of Health (NIH)

Timeline

Early Ph 1CompletedFinished
20222023202420252026
First PostedJan 24, 2022
Enrollment StartJan 24, 2024
Primary CompletionNov 8, 2024
TodayJul 1, 2026
Enrollment to primary: 9 monthsPosted 4.4 years ago

Interventions

MSC Secretome Eye Dropsbiological

MSC Secretome eye drop will be dispensed.